Duloxetine Capsule, Delayed Release
Product Images NDC 70247-014

Product Visual Gallery

This gallery contains 17 technical images submitted to the FDA as part of the official labeling for Duloxetine (NDC 70247-014). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Qingdao Baheal Pharmaceutical Co., Ltd., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Duloxetine Delayed-release Capsules Usp (Duloxetine 01)

Chemical structure diagram of duloxetine, depicting its molecular arrangement including aromatic rings, a thiophene group, and attached functional groups corresponding to the active ingredient duloxetine.*

FDA Label Image

Figure 1 (Duloxetine 18)

A line chart comparing the proportion of patients with relapse over time between treatment with Duloxetine and placebo. The x-axis represents time from randomization to relapse in days, ranging from 0 to 250, and the y-axis represents the proportion of patients with relapse, ranging from 0.0 to 1.0. The chart shows two lines: a dashed line for placebo and a solid line for Duloxetine, indicating a lower proportion of relapse with Duloxetine treatment over time.*

FDA Label Image

Figure 2 (Duloxetine 19)

A line graph depicting the proportion of patients with relapse over time from randomization in days, comparing treatment with duloxetine versus placebo. The X-axis represents days up to 300, and the Y-axis shows the proportion ranging from 0.0 to 1.0. The graph shows two lines: a solid line for duloxetine and a dashed line for placebo, illustrating relapse rates over the observed period.*

FDA Label Image

Figure 3 (Duloxetine 02)

A line graph depicting the percentage of patients improved versus percent improvement in pain from baseline for Duloxetine 60 mg taken twice daily (BID), Duloxetine 60 mg once daily (QD), Duloxetine 20 mg once daily (QD), and placebo. The graph compares the effectiveness of different Duloxetine dosages against placebo over incremental pain improvement percentages.*

FDA Label Image

Figure 4 (Duloxetine 03)

A line chart comparing the percentage of patients improved versus percent improvement in pain from baseline for duloxetine 60 mg BID, duloxetine 60 mg QD, and placebo. The x-axis represents percent improvement in pain from baseline (0 to 100%), and the y-axis shows percentage of patients improved (0 to 70%). Lines for duloxetine doses show higher percentages of patients improved across all pain improvement levels compared to placebo.*

FDA Label Image

Figure 5 (Duloxetine 05)

A line graph showing the percentage of patients improved versus percent improvement in pain from baseline. The graph compares duloxetine 60 mg twice daily, duloxetine 60 mg once daily, and placebo across varying degrees of pain improvement.*

FDA Label Image

Figure 6 (Duloxetine 06)

A line graph showing the percentage of patients improved plotted against percent improvement in pain from baseline for duloxetine capsules at 20 mg, 60 mg, and 120 mg once daily doses, compared to placebo. The graph indicates patient improvement trends across increasing levels of pain reduction for the three duloxetine doses versus placebo.*

FDA Label Image

Figure 8 (Duloxetine 15)

A line graph comparing percentage of patients improved versus percent improvement in pain from baseline (BOCF) for duloxetine 60/120 mg once daily and placebo groups. The vertical axis shows percent of patients improved (0-100%), and the horizontal axis shows percent improvement in pain from baseline (0-100%). Two lines represent duloxetine and placebo, with duloxetine consistently showing higher patient improvement rates across pain improvement percentages.*

FDA Label Image

Figure 9 (Duloxetine 16)

A line graph comparing the percentage of patients improved against the percent improvement in pain from baseline (BOCF). Two lines represent Placebo and Duloxetine 60 mg once daily, showing higher patient improvement percentages consistently with Duloxetine across pain improvement percentages from greater than 0 to 100.*

FDA Label Image

Figure 10 (Duloxetine 17)

A line graph comparing the percentage of patients improved versus percent improvement in pain from baseline (BOCF) for placebo and duloxetine 60/120 mg once daily. The graph shows two curves tracking improvements across increasing pain relief percentages from 0 to 100%.*

FDA Label Image

Package Label- Duloxetine Delayed-release Capsules 20 mg, Bottle Of 60 (Label 20mg)

Principal display panel of Duloxetine Delayed-Release Capsules, USP, 20 mg, containing 60 capsules. The label indicates the product is for prescription use only (Rx only) and includes instructions for pharmacists to dispense the Medication Guide separately. Manufactured by Qingdao BAHEAL Pharmaceutical Co., Ltd., China. The side panel notes the capsule contains 22.4 mg duloxetine hydrochloride equivalent to 20 mg duloxetine, storage instructions, and typical dispensing precautions.*

FDA Label Image

Package Label- Duloxetine Delayed-release Capsules 30 mg (Label 30mg)

Principal display panel and side panel of Duloxetine Delayed-Release Capsules, USP 30 mg. The label shows the NDC 70247-013-03 and specifies a package of 30 capsules. Manufactured by Qingdao BAHEAL Pharmaceutical Co., Ltd., Qingdao, Shandong, China. The side panel includes storage instructions, dosage guidance, and a barcode.*

FDA Label Image

Package Label- Duloxetine Delayed-release Capsules 30 mg (Label 30mg 90capsules)

Label for Duloxetine delayed-release capsules, USP 30 mg, containing 90 capsules. The label includes storage instructions, dosage guidance to see accompanying literature, and manufacturer information listing Qingdao BAHEAL Pharmaceutical Co., Ltd., Qingdao, Shandong, China. It is marked Rx only and displays the NDC 70247-013-09 and a barcode.*

FDA Label Image

Package Label- Duloxetine Delayed-release Capsules 30 mg (Label 30mg 1000capsules)

Label for Duloxetine delayed-release capsules, USP, 30 mg strength, with a quantity of 1000 capsules. The label instructs pharmacists to dispense the Medication Guide separately to patients and notes the product is Rx only. Manufactured by Qingdao BAHEAL Pharmaceutical Co., Ltd., Qingdao, Shandong, China, with storage instructions and barcode included.*

FDA Label Image

Package Label- Duloxetine Delayed-realease Capsules 60 mg (Label 60mg)

Duloxetine Delayed-Release Capsules, USP 60 mg label, containing 30 capsules. The label includes storage instructions, manufacturer information (Qingdao BAHEAL Pharmaceutical Co., Ltd., Qingdao, Shandong, China), and a barcode. It specifies that each capsule contains 67.3 mg duloxetine hydrochloride equivalent to 60 mg duloxetine and is for prescription use only.*

FDA Label Image

Package Label- Duloxetine Delayed-realease Capsules 60 mg (Label 60mg 60capsules)

Label for Duloxetine delayed-release capsules, USP 60 mg, containing 60 capsules. The label indicates the product is prescription only and produced by Qingdao BAHEAL Pharmaceutical Co., Ltd, Qingdao, Shandong, China. It includes storage instructions and a barcode with lot and expiration fields.*

FDA Label Image

Package Label- Duloxetine Delayed-realease Capsules 60 mg (Label 60mg 500capsules)

Label for Duloxetine Delayed-Release Capsules USDA, 60 mg strength, oral dosage form, containing 500 capsules. The label includes storage instructions, manufacturer information (Qingdao BAHEAL Pharmaceutical Co., Ltd.), and notes dispensing requirements. The NDC number 70247-014-50 and a barcode are visible.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.